Helicobacter pylori specifically colonizes the human gastric epithelium and is the major causative agent for ulcer disease and gastric cancer development. Here, we identify members of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as receptors of H. pylori and show that HopQ is the surface-exposed adhesin that specifically binds human CEACAM1, CEACAM3, CEACAM5 and CEACAM6. HopQ-CEACAM binding is glycan-independent and targeted to the N-domain. H. pylori binding induces CEACAM1-mediated signalling, and the HopQ-CEACAM1 interaction enables translocation of the virulence factor CagA into host cells and enhances the release of pro-inflammatory mediators such as interleukin-8. Based on the crystal structure of HopQ, we found that a β-hairpin insertion (HopQ-ID) in HopQ's extracellular 3+4 helix bundle domain is important for CEACAM binding. A peptide derived from this domain competitively inhibits HopQ-mediated activation of the Cag virulence pathway, as genetic or antibody-mediated abrogation of the HopQ function shows. Together, our data suggest the HopQ-CEACAM1 interaction to be a potentially promising novel therapeutic target to combat H. pylori-associated diseases.
C olonizing half of the world's population, Helicobacter pylori is one of the most prevalent human pathogens. Chronic inflammation elicited by this bacterium is the main cause of gastric cancer 1 . During co-evolution with its human host over more than 60,000 years 2 , the bacterium has acquired numerous adaptations for its long-term survival within its unique niche, the stomach. This includes the ability to buffer the extreme acidity of this environment, interference with cellular signalling pathways, evasion of the human immune response and a strong adhesive property to host cells 3 . Specifically, H. pylori persistence is facilitated by the binding of BabA and SabA adhesins to the human blood group antigen Leb and the sLex antigen, respectively [4] [5] [6] . However, adhesion to blood group antigens is not universal, is dynamically regulated during the course of infection and can also be turned off 7 . We observed that H. pylori is capable of binding to the human gastric epithelium of non-secretors. We thus hypothesized that the bacterium might be able to interact with other cell surface receptors to ensure persistent colonization.
Here, we show that the H. pylori adhesin HopQ specifically interacts with human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs). CEACAMs embrace a group of immunoglobulin superfamily-related glycoproteins with a wide tissue distribution. CEACAM1 can be expressed in leukocytes, endothelial and epithelial cells, CEACAM3 and CEACAM8 in granulocytes, CEACAM5 and CEACAM7 in epithelial cells and CEACAM6 in epithelia and granulocytes. In epithelial cells, transmembrane-anchored CEACAM1 as well as glycosylphosphatidylinositol-linked CEACAM5, CEACAM6 and CEACAM7 localize to the apical membrane 8 . CEACAMs modulate diverse cellular functions, including cell adhesion, differentiation, proliferation and cell survival. Some CEACAMs have been recognized as valuable tumour markers due to their increased expression in malignant tissue and increased sera level 9 . In recent years, CEACAMs have also emerged as immunomodulatory mediators 10 . Interestingly, in humans, several CEACAMs have been found to specifically interact with bacteria such as Neisseria, Haemophilus influenzae, Moraxella catarrhalis and Escherichia coli 11 .
H. pylori binds to CEACAMs expressed in human stomach
Based on the observation that H. pylori efficiently colonizes individuals in the absence of Lewis blood group antigens 12 on the one hand and the increased expression of members of the CEACAM family in gastric tumours, we hypothesized that H. pylori may use CEACAMs as receptors. Using pulldown and flow cytometric approaches we found a robust interaction of H. pylori strain G27 with recombinant human CEACAM1-Fc (Fig. 1a) , comparable to that of Moraxella catarrhalis ( Supplementary Fig. 1a ,b). As negative control, Moraxella lacunata did not bind to human CEACAM1, nor did Campylobacter jejuni, a pathogen closely related to H. pylori ( Supplementary Fig. 1a ,b). When testing for CEACAM specificity, we also observed a clear interaction of H. pylori with CEACAM3, 5 and 6, but not with CEACAM8 Figure 1 | H. pylori employs the N-terminal domain of human CEACAM1 and binds CEACAM5 and CEACAM6 but not CEACAM8. a,b, H. pylori G27 strain binding to human CEACAM1-Fc (a) and human CEACAM5-Fc, CEACAM6-Fc or CEACAM8-Fc (b) was analysed by pulldown experiments followed by western blot analysis and flow cytometry. One representative of three independent experiments is shown. Bacteria not incubated with CEACAMs served as negative control (grey line). c, CEACAM1, CEACAM5 and CEACAM6 expression detected by immunohistochemistry in human normal stomach, gastritis and gastric cancer samples. Representative images (n = 10 tissue samples for each condition) are shown. Scale bars, 50 µm. d, Binding of H. pylori to human CEACAM1ΔN-Fc (lacking the complete N-domain) detected by western blot after pulldown or by flow cytometry. One representative experiment of four is shown. Bacteria not incubated with CEACAM served as negative control (grey line). e, H. pylori binding to CEACAM variants analysed by flow cytometry. Mean fluorescence intensity (MFI) ratios (mean ± s.d.) of one representative experiment (n = 4) are shown. Bacteria not incubated with CEACAMs served as negative control (grey line). One-way ANOVA, P = 0.009; NS, not significant.
( Fig. 1b and Supplementary Fig. 1c,d) . Importantly, all H. pylori strains tested bound to these CEACAMs ( Supplementary Fig. 1f,  g ), including well-characterized reference strains (26695, J99) and the mouse-adapted strain SS1. However, the binding strength differed among strains, with some preferentially binding to CEACAM1 and others to CEACAM5 and/or CEACAM6 ( Supplementary Fig. 1f,g ). We then analysed the expression profiles of CEACAM1, CEACAM5 and CEACAM6 in normal and inflamed human stomach tissues and gastric cancer. If at all, only low levels of CEACAM1 and CEACAM5 were expressed at the apical side of epithelial cells and their expression, as well as that of CEACAM6, was upregulated upon gastritis and in gastric tumours ( Fig. 1c and Supplementary Fig. 1e ). During infection, H. pylori-induced responses may thus lead to increased expression of its CEACAM receptors.
Adhesins from other bacteria have been shown to specifically bind to the N-domain of human CEACAM1 13, 14 . Similarly, we found that lack of the CEACAM1 N-domain abolished H. pylori binding completely (Fig. 1d) . Although for the interaction of Neisseria meningitidis with CEACAM1 the N-domain was necessary but not sufficient for binding 15 , we observed binding of H. pylori to all tested CEACAM1 isoforms containing the N-domain, as well as to the N-domain alone (Fig. 1e) . However, binding to the N-domain alone was weaker than to the N-A1-B CEACAM1 variant, which bound less than the N-A1-B-A2 variant ( Fig. 1e and Supplementary Fig. 1j ), suggesting that these domains stabilize the CEACAM1-H. pylori interaction. Comparison of the respective N-domains indicated several residues conserved in CEACAM1, 5 and 6 but not in CEACAM8 ( Supplementary Fig. 1h ).
Species specificity of Helicobacter-CEACAM interaction
Although murine and Mongolian gerbil models are routinely used to study gastric infection with H. pylori, the bacterium, so far, has been described to be naturally transmitted to only humans and non-human primates. While CEACAMs are found in most mammalian species and have a high degree of conservation, we found that H. pylori bound selectively to human, but not to mouse, bovine or canine CEACAM1 orthologues (Fig. 2a) . However, we were surprised to find a strong interaction of H. pylori with rat CEACAM1 (Fig. 2b,d ). This interaction was also mediated through the N-domain of rat CEACAM1 (Fig. 2c,d ). To substantiate these findings, we transfected human, mouse or rat CEACAM1 into Figure 2 | H. pylori binding to CEACAM1 orthologues. a, H. pylori G27 strain binding to human, murine, bovine and canine CEACAM1 determined by flow cytometry. Bacteria not incubated with CEACAMs served as negative control (grey line). b,c, H. pylori (G27) binding to rat CEACAM1-Fc (b) and rat CEACAM1ΔN-Fc (c) detected by western blot after bacterial pulldown. d, Binding of G27 H. pylori strain to rat CEACAM1 and rat CEACAM1ΔN detected by flow cytometry. Bacteria not incubated with CEACAMs served as negative control (grey line). e, Representative confocal images of H. pylori (green) binding to human, rat and mouse CEACAM1-expressing CHO cells. Cell membranes were stained with Deep Red and nuclei with DAPI (blue). Untransfected CHO cells served as control. Scale bars: left panels, 25 µm; right panels, 10 µm. f, H. pylori G27 pulldown of whole cell lysates of untransfected, human, mouse and rat CEACAM1-transfected CHO cells. CEACAM1 was detected using species-specific CEACAM1 antibodies, as indicated. Representative experiments for all panels are shown (n = 3).
CHO cells, to which H. pylori does not adhere otherwise. Using confocal laser scanning microscopy, we observed de novo adhesion of H. pylori to CHO cells expressing human and rat, but not mouse CEACAM1 (Fig. 2e) , which could be confirmed by pulldown and western blotting of lysates from transfected cells ( Fig. 2f and Supplementary Fig. 2d ). This finding makes H. pylori the first pathogen for which its CEACAM binding is not restricted to one species. Comparing the protein sequences of the CEACAM1 N-domains, several amino acids conserved in human and rat differ in mouse (asn10, glu26, asn42, tyr48, pro59, thr66, asn77, val79, val89, ile90, glu103, tyr108; Supplementary Fig. 2a ). In addition, our findings of the lack of binding to mouse CEACAM1 may explain the differences seen in pathology between infected mice and humans 16 . The genus Helicobacter comprises several other spp., that is, H. felis, suis and bizzozeronii as well as the human pathogenic H. bilis and H. heilmannii. When assessing the interaction of these Helicobacters with human CEACAMs, only H. bilis bound to human CEACAM1, 5 and 6 ( Supplementary Fig. 2b,c) . As with H. pylori, H. bilis interacted with the N-domain of human CEACAM1 ( Supplementary Fig. 2b,c) . This interaction may explain how H. bilis manages to colonize human bile ducts, where high levels of constitutively expressed CEACAM1 are present.
HopQ is the H. pylori adhesin interacting with CEACAMs
To identify the CEACAM-binding partner in H. pylori, we initially screened a number of H. pylori mutants devoid of defined virulence factors that have been shown to be implicated in various modes of host cell interaction (BabA, SabA, AlpA/B, VacA, gGT, urease and the cagPAI) 5, 6, 17 . All of these mutants still bound to human CEACAM1 (Fig. 3a) . We therefore established an immunoprecipitation approach ( Supplementary Fig. 3a ) using H. pylori lysate and recombinant human CEACAM1-Fc coupled to protein G. Mass spectrometric analysis of the co-precipitate identified two highly conserved H. pylori outer membrane proteins as candidate CEACAM1 adhesins: HopQ and HopZ (Supplementary Tables 1 and 2 ). Unlike a hopZ mutant, a hopQ deletion mutant was devoid of CEACAM1 binding (Fig. 3b) . Importantly, the hopQ mutant was also unable to bind to CEACAM5 and 6 (Fig. 3b ).
Next, we tested the binding of recombinant HopQ to different gastric cancer cell lines and found that HopQ interacted with AGS and MKN45, both endogenously expressing CEACAMs ( Supplementary Fig. 3b ). HopQ did not bind to the CEACAM negative cell line MKN28. Using our CHO transfectants, we found that the recombinant HopQ interacted preferentially with CEACAM1 and 5, and to lesser extent to CEACAM3 and 6. No binding was observed to CHO cells expressing either CEACAM4, 7 or 8 ( Supplementary Fig. 3c ).
HopQ is a member of a H. pylori-specific family of outer membrane proteins and shows no significant homology to other CEACAM-binding adhesins from other Gram-negative bacteria (that is, Opa proteins or UspA1 from Neisseria meningitidis and Neisseria gonorrhoeae or Moraxella catarrhalis, respectively) and is therefore a novel bacterial factor hijacking CEACAMs. Like Opa and UspA1 (refs 13,14) , HopQ targets the N-terminal domain in CEACAMs, an interaction we found to require folded protein (see section 'Structure and binding properties of HopQ adhesion domain') and was dependent on CEACAM sequence, resulting in specificity for human CEACAM1, 3, 5 and 6. The H. pylori hopQ gene (omp27; HP1177 in H. pylori reference strain 26695) exhibits genetic diversity that represents two allelic families 18 , type I and type II ( Supplementary Fig. 3d ), of which the type-I allele is found more frequently in cag(+)/s1-vacA type strains. Both alleles share 75-80% nucleotide sequences and exhibit a homology of 70% at the amino acid level 18 . Importantly, the hopQ genotype shows a geographic variation, with the hopQ type-I alleles more prevalent in Asian than Western strains, and was also found to correlate with strain virulence, with type-I alleles associated with higher inflammation and gastric atrophy 19 .
Structure and binding properties of HopQ adhesion domain
HopQ belongs to a paralogous family of H. pylori outer membrane proteins (Hop), to which the blood group antigen-binding adhesins BabA and SabA also belong 5, 6, 17, 20 . To gain insight into its structurefunction relationship we determined the binding properties and X-ray structure of a HopQ fragment corresponding to its predicted extracellular domain (residues 17-444 of the mature protein; HopQ AD ; Fig. 4a ). HopQ AD showed strong, dose-dependent binding to the N-terminal domain of human CEACAM1 (C1ND; residues 35-142) in an enzyme-linked immunosorbent assay (ELISA; Fig. 4b ), and isothermal titration calorimetry (ITC) revealed a 1:1 stoichiometry with a dissociation constant of 296 ± 40 nM (Supplementary Fig. 4a ). The HopQ AD X-ray structure shows that, like BabA and SabA, the HopQ ectodomain adopts a 3+4-helix bundle topology, although it lacks the extended coiledcoil 'stem' domain that connects the ectodomain to the transmembrane region ( Fig. 4a and Supplementary Fig. 4d ). In BabA, the carbohydrate binding site resides fully in a four-stranded β-domain that is inserted between helices 4 and 5 (ref. 21 ; Supplementary Fig. 4d ). In HopQ, a two-stranded β-hairpin is found in this position (residues 180-218). Removal of the β-hairpin resulted in a soluble protein that showed an approximately tenfold reduction of CEACAM1 binding affinity ( Fig. 4b and Supplementary Fig. 4c ), indicating that although the HopQ insertion domain is implicated in binding, it does not comprise the full binding site as found in BabA (Fig. 4b) .
The hitherto characterized Hop adhesins are lectins 5, 6, 17, 22 . However, H. pylori was seen to retain binding to CEACAM1 upon enzymatic deglycosylation, and far western analysis revealed that HopQ AD specifically bound folded, but not denatured C1ND (Fig. 4c) , suggesting that HopQ-CEACAM binding relies on protein-protein rather than glycan-dependent interactions. Indeed, ITC binding profiles of HopQ AD titrated with non-glycosylated E. coli expressed C1ND (Ec-C1ND) revealed an equimolar interaction with a dissociation constant of 417 ± 48 nM ( Supplementary Fig. 4b ), showing that CEACAM N-glycosylation only provides a minor stabilizing contribution to the HopQ-CEACAM interaction. To further map the HopQ binding site, we pre-incubated CEACAM1 with the M. catarrhalis adhesin UspA1, and found that this prevented binding by H. pylori (Fig. 4d) , suggesting that both adhesins have overlapping binding epitopes. In further support, mutation of CEACAM1 residues Y34 or I91 within the UspA1 binding epitope reduced or nearly abrogated CEACAM1 binding by H. pylori (Fig. 4e) . Interestingly, I91 is conserved in rat but mutated to T in mouse CEACAM1, possibly explaining the observed species specificity in HopQ binding ( Supplementary Fig. 2a , see Section 'Species specificity of Helicobacter-CEACAM interaction').
HopQ-CEACAM1 interaction triggers cell responses
Available animal models only partially replicate the H. pylori pathogenesis observed in its human host, and mouse CEACAMs did not support HopQ binding. Therefore, to further investigate how HopQ may influence adhesion and cellular responses, we sought to establish cellular pathogenesis models in which the HopQ-CEACAM mediated adhesion could be analysed. According to Singer et al. 23 , we characterized various gastric cell lines typically employed for H. pylori in vitro experiments regarding their expression of CEACAMs and observed that MKN45, KatoIII and AGS did express CEACAM1, 5 and 6, whereas MKN28 showed no presence of CEACAMs ( Supplementary Fig. 5a,b) . In parallel, CHO cells were stably transfected with CEACAM1-L (containing the immunoreceptor tyrosine-based inhibition motif, ITIM). Upon infection with H. pylori wild-type strain P12 and its isogenic hopQ deletion mutant, we observed a significantly reduced adherence to CHO-CEACAM1-L, MKN45 and AGS cells when hopQ was not present, while strains deficient in the adhesins BabA and SabA showed only slightly reduced adhesion ( Fig. 5a and Supplementary Fig. 5c ). HopQ binding was also studied in human gastric biopsies from H. pylori infected individuals. Here, we detected that HopQ bound to the apical side human gastric epithelium and co-localized with CEACAM in biopsies from H. pylori infected individuals ( Fig. 5b and Supplementary Fig. 5d ), while no binding was observed in CEACAM1 negative samples from normal stomach (not shown). In CHO-CEACAM1-L cells, we observed tyrosine-phosphorylation of the CEACAM1 ITIM domain on exposure to H. pylori, which was apparent within 5 min and was maintained for up to 1 h (Fig. 5c) . Phosphorylation of the CEACAM1 ITIM domain is a well-known initial event triggering SHP1/2 recruitment inducing downstream signalling cascades 24, 25 . Contact-dependent signalling through 
Pulldown kDa 120 CEACAMs is a common means of modulating immune responses related to infection, inflammation and cancer 10 , and these immunedampening cascades probably reflect the multiple independent emergence of non-homologous CEACAM-interacting proteins in diverse mucosal Gram-negative pathogens including Neisseria, Haemophilus, Escherichia, Salmonella and Moraxella sp. (refs 13,14) . For H. pylori, interaction with 
HopQ-ID *** *** *** *** *** *** *** *** *** *** *** *** *** *** human CEACAM1 through HopQ may represent a critical parameter for immunomodulatory signalling during colonization and chronic infection of man. Additionally, hopQ mutant H. pylori strains showed an almost complete loss of cagPAI-dependent CagA translocation (Fig. 5d ) and strongly reduced IL-8 induction (Fig. 5e ), while loss of other known adhesins had no effect on CagA delivery ( Supplementary  Fig. 5e,f ) . This is in line with a previous study showing that in AGS gastric cancer cells, a hopQ mutant H. pylori strain exhibited reduced ability to activate NF-κB and altered translocation of CagA (ref. 26) . In contrast to our findings, Belogolova et al. did not observe reduced adherence of a hopQ mutant H. pylori P12 strain, which could be due to the observed growth-dependent expression of CEACAMs in these cells.
To corroborate our data in an independent model and compensate for potential clonal effects in stably transfected cells, we transiently transfected HEK293 cells with human CEACAM (1-L, 3, 4, 5, 6, 7, 8) expression plasmids. Infection of these cells confirmed the defect in CagA translocation observed in CHO-CEACAM1-L cells, which was restored on complementation of the hopQ mutant strain (P12ΔhopQhopQ + ) ( Fig. 5f and Supplementary  Fig. 5g ). Also, cellular elongation, the so-called 'hummingbird phenotype', was significantly reduced following deletion of hopQ (Fig. 5g,h) . Furthermore, we observed that H. pylori modulates important host transcription factors such as Myc or STAT3, in a hopQ-dependent fashion (Supplementary Fig. 5h ). Our results reveal that HopQ-CEACAM binding leads to direct and indirect alterations in host cell signalling cascades, and start to shed light on these HopQ-associated virulence landscapes. Given the importance of these signalling events for gastric carcinogenesis, we explored whether the CEACAM-HopQ interaction could be targeted in order to prevent CagA translocation and downstream effects. Indeed, incubation of the cells with an α-CEACAM1 antibody, α-HopQ antiserum or a HopQ-derived peptide corresponding to the Hop-ID (aa 189-220) reduced CagA translocation in a dosedependent manner (Fig. 5i-k) , while corresponding controls did not ( Supplementary Fig. 5i ). These data demonstrate that the HopQ-CEACAM1 interaction is necessary for successful translocation of the oncoprotein CagA into epithelial cells as well as modulation of inflammatory signalling, and that interference with this interaction can prevent CagA translocation, giving an indication of the translational potential of HopQ targeting for H. pylori vaccination or immunotherapy.
Deletion of hopQ abrogates H. pylori colonization
As we have found binding of HopQ to human and rat, but not to mouse CEACAM, we finally determined the role of HopQ in vivo, using a rat model of H. pylori infection. Having observed that CEACAM1 was expressed in normal rat stomach (Fig. 6a and Supplementary Fig. 6b ), we infected rats with the mouse-adapted strain SS1, able to bind human and rat CEACAM1 ( Supplementary Fig. 6a ). Although the wild-type SS1 was able to colonize rats efficiently, albeit at lower levels compared to the mouse (Fig. 6b) , the hopQ-deficient SS1 strain was not able to colonize rats at detectable levels and could not induce an inflammatory response in comparison to the wild-type SS1 strain (Fig. 6b,c) . From these data, it seems likely that HopQ also serves as an important factor to mediate H. pylori colonization, but only further work will be able to determine whether HopQ-CEACAM interaction is required for bacterial colonization. Infection of rats with H. pylori has been described 27 , but our finding may allow the establishment of an animal model for studying H. pylori infection that better replicates the prevailing virulence pathways.
Discussion
The CEACAM-binding property identified here provides H. pylori with a means of epithelial adherence in addition to the Lewis antigens used by the BabA and SabA adhesins 5, 6, 17 . Although overexpression of CEACAMs in gastrointestinal tumours is well described, their upregulation during H. pylori-induced inflammation in the stomach has not been reported so far, suggesting that the pathogen has the ability to shape its own adhesive niche. A similar phenomenon has also been observed for the inflammation-induced upregulation of sialylated antigens that form the receptors for the SabA adhesin 6 . A plausible route to CEACAM modulation is through transcription factors NF-κB and AP1, both of which are induced during H. pylori infection 28 and are known to regulate CEACAM expression 29 . Although HopQ-dependent adherence may appear redundant to that of other adhesins like BabA, SabA or LabA, HopQ specializes in human CEACAMs and is required for cagPAI functionality. From the perspective of hostpathogen (that is, human-H. pylori) co-evolution, the primary function of HopQ may lie in immune-modulation through CEACAM binding, and HopQ's indirect effects on other virulence cascades elicited by H. pylori, such as that induced by increased CagA delivery, may not have been 'intended' initially. The cagPAI was acquired by ancestral H. pylori in a single event that occurred before modern humans migrated out of East Africa around 58,000 years ago 30 . Thus, it is likely that the employment of CEACAM1 ligation by H. pylori occurred much earlier to support colonization and to modulate immune responses. This assumption is supported by the fact that all fully sequenced H. pylori strains bear hopQ (Supplementary Fig. 3d ), indicating that this is an essential outer membrane protein of H. pylori. Following the occurrence of type-I H. pylori strains by cagPAI acquisition more than 60,000 years ago 30 , this ancient survival strategy was further implemented into a mechanism supporting pathogenicity and thus may have contributed to the evolution from commensal to pathogenic H. pylori 31 . Pathogenicity might even be further aggravated by our observation that CEACAMs are strongly upregulated during gastritis, which further potentiates binding of H. pylori to epithelial cells and specifically facilitates CagA/cagPAI interaction with the host cells.
Taken together, the finding that H. pylori employs CEACAMs not only for bacterial adherence but also to induce cellular signalling may lead to a better understanding of the pathogenic mechanisms of these bacteria and might lead to novel therapeutic approaches to more effectively combat this highly prevalent infection and the associated gastric pathology.
Methods
Bacteria and bacterial growth conditions. H. pylori strains G27 (ref. 32 41 on brain-heart infusion (BHI) agar supplemented with 10% horse blood. Moraxella catarrhalis (ATCC 25238) was provided by C. R. Hauck (Konstanz Research School Chemical Biology, University of Konstanz, Germany), and Moraxella lacunata (ATCC 17967) and Campylobacter jejuni (ATCC 33560) were cultured on BHI agar supplemented with 5% heated horse blood overnight at 37°C in a CO 2 incubator. The generation of an isogenic ΔhopQ mutant was achieved by replacement of the entire gene by a chloramphenicol resistance cassette. For genetic complementation of hopQ, the 1,926 bp gene fragment of H. pylori strain P12 was amplified by PCR. This fragment was cloned into complementation vector pSB1001 using the AphA3 cassette for selection. This fusion construct was introduced in the plasticity region of strain P12ΔhopQ (between open reading frames HP0999 and HP1000) using a strategy as described in ref. 42 .
Production of CEACAM proteins. The cDNA, which encodes the extracellular domains of human CEACAM1-Fc (consisting of N-A1-B1-A2 domains), human CEACAM1dN-Fc (consisting of A1-B1-A2, lacking the first 143 amino acids of the N-terminal IgV-like domain), rat CEACAM1-Fc (consisting of N-A1-B1-A2), rat CEACAM1dN-Fc (consisting of A1-B1-A2), human CEACAM3-Fc (consisting of N), human CEACAM6-Fc (consisting of N-A-B) and human CEACAM8-Fc (consisting of N-A-B), respectively, was fused to a human heavy-chain Fc-domain and cloned into the pcDNA3.1(+) expression vector (Invitrogen), sequenced and stably transfected into HEK293 (ATCC CRL-1573) cells as described in ref. 43 . The Fc chimaeric CEACAM-Fc proteins were accumulated in serum-free Pro293s-CDM medium (Lonza) and were recovered by protein A/G-Sepharose affinity chromatography (Pierce). Proteins were analysed by SDS-PAGE and stained by Coomassie blue, demonstrating an equal amount and integrity of the produced fusion proteins (Supplementary Fig. 1i ). Recombinant-human CEACAM5-Fc was ordered from Sino Biological. The GFP-tagged CEACAMs (human CEACAM1 and its variants, mouse CEACAM1, bovine CEACAM1 and canine CEACAM1) were provided by C.R. Hauck (University Konstanz, Germany). For the production of the recombinant human CEACAM1 N-domain (C1ND), the annotated domain (residues 35-142 of CEACAM1, Uniprot ID: P13688) was first backtranslated using the Gene Optimizer (Life Technologies), and the leader sequence of the Igk-chain as well as a C-terminal Strep-Tag II was added. The gene was synthesized and seamlessly cloned into pCDNA3.4-TOPO (Life Technologies). Protein was produced in a 2 l culture of Expi293 cells according to the Expi293 expression system instructions (Life Technologies). The resulting supernatant was concentrated and diafiltered against ten volumes of 1× streptavidin affinity chromatography (SAC) buffer (100 mM Tris-HCl, 140 mM NaCl, 1 mM EDTA, pH 8.0) by crossflowfiltration, using a Hydrosart 5 kDa molecular-weight cutoff membrane (Sartorius). The retentate was loaded onto a StrepTrap HP column (GE Healthcare) and eluted with 1× SAC supplemented with 2.5 mM D-desthiobiotin (IBA). The protein was stored at +4°C.
For the bacterial expression of the C1ND (Ec-C1ND) the amino acid sequence (residues 35-142 of CEACAM1, Uniprot ID: P13688) was codon optimized for expression in E. coli, synthesized by GeneArt de novo gene synthesis (Life Technologies) and cloned with a C-terminal His6 tag in the pDEST TM 14 vector using Gateway technology (Invitrogen). E. coli C43(DE3) cells were transformed with the resulting construct and grown in LB supplemented with 100 µg ml -1 ampicillin at 37°C while shaking. At an optical density at 600 nm (OD 600 ) of 1 Ec-C1ND expression was induced with 1 mM isopropyl-β-D-thiogalactopyranoside overnight at 30°C. Cells were collected by centrifugation at 6.238g for 15 min at 4°C and resuspended in 50 mM Tris-HCl pH 7.4, 500 mM NaCl (4 ml g -1 wet cells) supplemented with 5 µM leupeptin and 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), 100 µg ml -1 lysozyme and 20 µg ml -1 DNase I. Subsequently, cells were lysed by a single passage in a Constant System Cell Cracker at 20 kpsi at 4°C and debris was removed by centrifugation at 48,400g for 40 min. The cytoplasmic extract was filtrated through a 0.45 µm pore filter and loaded on a 5 ml pre-packed Ni-NTA column (GE Healthcare) equilibrated with buffer A (50 mM Tris-HCl pH 7.4, 500 mM NaCl and 20 mM imidazole). The column was then washed with 40 bed volumes of buffer A and bound proteins were eluted with a linear gradient of 0-75% buffer B (50 mM Tris-HCl pH 7.4, 500 mM NaCl and 500 mM imidazole). Fractions containing Ec-C1ND, as determined by SDS-PAGE, were pooled and concentrated in a 10 kDa molecular weight cutoff spin concentrator to a final volume of 5 ml. To remove minor protein contaminants, the concentrated sample was injected onto the Hi-Prep 26/60 Sephacryl S-100 HR column (GE Healthcare) pre-equilibrated with a buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl. Fractions containing the Ec-C1ND complex were pooled and concentrated using a 10 kDa molecular weight cutoff spin concentrator.
HopQ
AD and HopQ AD ΔID cloning, production and purification. To obtain a soluble HopQ fragment, the HopQ gene from the H. pylori G27 strain (accession no. CP001173; Region 1228696..1230621) HopQ fragment from residues 37 to 463 was produced (residues 17-444 of the mature protein), thus removing the N-terminal β-strand and signal peptide, as well as the C-terminal β-domain expected to represent the TM domain. In HopQ AD ΔID, amino acids 184-212 of the mature protein were replaced by two glycines (Supplementary Fig. 4e ). DNA coding sequences corresponding to the HopQ type I fragments were PCR-amplified from H. pylori G27 genomic DNA using primers (forward: GTTTAACTTTAA GAAGGAGATATACAAATGGCGGTTCAAAAAGTGAAAAACGC; reverse: TCAAGCTTATTAATGATGATGATGATGGTGGGCGCCGTTATTCGTGGTTG) containing 30 bp overlap to the flanking target vector sequences of pPRkana-1, a derivative of pPR-IBA 1 (IBA) with the ampicillin resistance cassette replaced by the kanamycin resistance cassette, under a T7 promotor. In parallel, the vector was PCR-amplified using primers (forward: CACCATCATCATCATCATTAATAAGCT TGATCCGGCTGCTAAC ; reverse: GTTTAACTTTAAGAAGGAGATATACAAA TG) using the same overlapping sequences in reversed orientation. The forward primer also carried the sequence for a 6× His-tag. The amplicons were seamlessly cloned using Gibson Assembly (New England Biolabs). Based on the codon optimized HopQ AD plasmid, the HopQ AD ΔID constructs were cloned. The plasmids were amplified by 5′ phosphorylated primers (forward: GGTGACGCTCAGAACCT GCTGAC; reverse: ACCACCTTTAGAGTTCAGCGGAG), replacing the ID region by two glycines, DpnI (NEB) digested and blunt-end ligated by T4 ligase (NEB).
E. coli BL21(DE3) cells (NEB) were transformed with the pPRkana-1 constructs, grown at 37°C at 275 r.p.m. on auto-inducing terrific broth (TRB) according to Studier 44 , supplemented with 2 mM MgSO 4 , 100 mg l -1 kanamycin-sulfate (Carl Roth), 0.2 g l -1 PPG2000 (Sigma-Aldrich) and 0.2% wt/vol lactose-monohydrate (Sigma-Aldrich), until an OD of 1-2 was reached. Afterwards, the temperature was lowered to 25°C and auto-induced overnight, reaching a final OD of 10-15 the following morning. Cells were collected by centrifugation at 6,000g for 15 min at 4°C using an SLA-3000 rotor in a Sorvall RC-6 Plus centrifuge (Thermo Fischer). Before cell disruption, cells were resuspended in 10 ml cold NiNTA buffer A (500 mM NaCl, 100 mM Tris-HCl, 25 mM imidazole, pH 7.4) per gram of biological wet weight (BWW), supplemented with 0.1 mM AEBSF-HCl, 150 U g −1 BWW DNase I and 5 mM MgCl 2 and dispersed with an Ultra-Turrax T25 digital (IKA). Cell disruption was performed by high-pressure homogenization with a PANDA2000 (GEA NiroSoavi) at 800-1,200 bar in three passages at 4°C. The cell lysate was clarified by centrifugation at 25,000g for 30 min at 4°C in a SLA-1500 rotor and remaining particles were removed by filtration through a 0.2 µm filter.
HopQ fragments were purified by consecutive nickel affinity and size exclusion chromatography. Briefly, the clarified cell lysate was loaded onto a 5 ml pre-packed Ni-NTA HisTrap FF crude column (GE Healthcare) pre-equilibrated with buffer A, washed with ten column volumes (CVs) of buffer A and the bound protein eluted with a 15 CV linear gradient to 75% NiNTA buffer B (500 mM NaCl, 100 mM Tris-HCl, 500 mM imidazole, pH 7.4). Eluted peak fractions were collected, pooled and concentrated to a final concentration of 8-10 mg ml −1 using a 10 kDa molecular-weight cutoff spin concentrator. Subsequently, 5 ml of the concentrated protein were loaded onto a HiLoad 16/600 Superdex 75 pg column (GE Healthcare) pre-equilibrated with Buffer C (5 mM Tris-HCl, 140 mM NaCl, pH 7.3) and eluted at 1 ml min -1 . Finally, only protein corresponding to the monomer-peak was pooled and stored at +4°C before crystallization. To analyse the multimerization state of HopQ AD , SEC was performed on a Superdex 200 10/300 GL (GE Healthcare) with 24 ml bed volume. The column was pre-equilibrated with Buffer C, then 25 µg protein was injected and separated with a flow rate of 0.5 ml min -1 . The HopQ interaction domain (HopQ-ID) representing peptide was HA-tagged, synthesized (EKLEAHVTTSKYQQDNQTKTTTSVIDTTNYPYDVPDYA) and HPLC purified (Peptide Specialty Laboratories). For cellular assays, the lyophilized peptide was dissolved in sterile PBS to a concentration of 1 mM and dialysed with a 0.1-0.5 kDa molecular-weight cutoff membrane against PBS to remove remaining trifluoroacetic acid (TFA). The peptide solution was stored at −20°C until further use.
Detection of the HopQ-CEACAM interaction by ELISA. For detection of the interaction between CEACAM and HopQ AD , recombinant C1ND (1 µg ml -1 ) in PBS was coated overnight at 4°C onto a 96-well immunoplate (Nunc MaxiSorb). Wells were blocked with SmartBlock (Candor) for 2 h at room temperature.
Subsequently, HopQ fragments were added in a fivefold series dilution ranging from 10 µg ml -1 to 0.05 ng ml -1 for 2 h at room temperature. Next, anα-6× His-HRP conjugate (clone 3D5, Life Technologies) was diluted 1:5,000 and incubated for 1 h at room temperature. For detection, 1-Step Ultra TMB-ELISA Substrate Solution (Life Technologies) was used and the enzymatic reaction was stopped with 2 N H 2 SO 4 . Washing (three to five times) between incubation steps was carried out with PBS/0.05% Tween 20.
Isothermal titration calorimetry. ITC measurements were performed on a MicroCal iTC200 calorimeter (Malvern). C1ND or EcC1ND (25 µM) were loaded into the cell of the calorimeter and 250 µM HopQ AD type I was loaded into the syringe. All measurements were performed at 25°C, with a stirring speed of 600 r.p.m., in 20 mM HEPES buffer (pH 7.4), 150 mM NaCl, 5% (vol/vol) glycerol and 0.05% (vol/vol) Tween 20. Binding data were analysed using the MicroCal LLC ITC200 software.
SDS-PAGE and native-PAGE for western blot. CEACAM was separated with both SDS-PAGE and native-PAGE (on 15 and 7.5% polyacrylamide gels, respectively) in ice-cold 25 mM Tris-HCl, 250 mM glycine buffer. Subsequently, samples were transferred to polyvinylidene difluoride membranes by wet blotting at 25 V for 60 min in ice-cold transfer buffer (25 mM Tris-HCl, 250 mM glycine and 20% methanol). Membranes were blocked for 1 h in 10% milk powder (MP), 1× PBS and 0.005% Tween 20. The membranes were washed and incubated together in 5% MP, 1× PBS, 0.005% Tween 20 in the presence of 2 µM HopQ AD type I for 1 h to allow complex formation between HopQ AD I and CEACAM. After a washing step, the C-terminal His-tag of HopQ (CEACAM is strep tagged) was detected by adding, consecutively, mouse α-His (AbDSerotec) and goat α-mouse antibody (Sigma-Aldrich) for 1 h and 30 min, respectively, in 5% MP, 1× PBS, 0.005% Tween 20. After a washing step, the blot was developed by adding BCIP/NBT substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium) (Roche) in developing buffer (10 mM Tris-HCl pH 9.5, 100 mM NaCl, 50 mM MgCl 2 ).
Bacterial pull down. Bacteria were grown overnight on WC dent agar plates. Bacteria were scraped from plates, suspended in PBS, and colony-forming units (c.f.u.) were estimated by OD 600nm readings according to a standard curve. Bacteria were washed twice with PBS and 2 × 10 8 cells ml -1 were incubated with soluble CEACAM-Fc or CEACAM-GFP proteins or CHO cell lysates for 1 h at 37°C, with head-over-head rotation. After incubation, bacteria were washed five times with PBS and either boiled in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% wt/vol SDS, 10% glycerol, 50 mM dithiothreitol (DTT) and 0.01% wt/vol bromophenol blue) before SDS-PAGE and western blotting or taken up in FACS buffer (PBS/0.5% bovine serum albumin, BSA) for flow cytometry analysis.
Immunoprecipitation and mass spectrometry. Bacteria (2 × 10 8 ) in cold PBS containing protease and phosphatase inhibitors (Roche) were lysed by ultrasonication on ice (ten times, 20 s). Cell debris was removed from the lysates by centrifugation at 15,000 r.p.m. for 30 min at 4°C, followed by pre-clearing with prewashed protein G-agarose (Roche Diagnostics). CEACAM1-Fc was added to the lysate (10 µg) and incubated for 1 h at 4°C. Prewashed protein G-agarose (60 µl) was added to the antibody and lysate mixture and incubated 2 h at 4°C. Beads were washed with PBS five times to remove unspecifically bound proteins. Two-thirds of the beads were separated and used for mass spectrometry sample preparation. The supernatant was removed and the beads were resuspended twice in 50 µl 7 M urea/ 2 M thiourea dissolved in 20 mM HEPES (pH 7.5) for denaturation of the proteins. Beads were pelleted by centrifugation, and the supernatants were pooled and transferred to a new Eppendorf tube. Proteins were then reduced in 1 mM DTT for 45 min and alkylated at a final concentration of 5.5 mM iodacetamide for 30 min in the dark. The alkylation step was quenched by raising the DTT concentration to 5 mM for 30 min. All incubation steps were carried out at room temperature under vigorous shaking (Eppendorf shaker, 450 r.p.m.). For digestion of the proteins, 1 µl LysC (0.5 µg µl -1 ) was added, and the sample incubated for 4 h at room temperature. To reduce the urea concentration the sample was diluted 1:4 with 50 mM triethylammonium bicarbonate and then incubated with 1.5 µl trypsin (0.5 µg µl -1 ) at 37°C over night. Trypsin was finally inactivated by acidification with formic acid. The supernatant was transferred to a new Eppendorf tube and pooled with the following wash fraction of the beads with 0.1% formic acid. The sample was adjusted to pH 3 with formic acid (100% vol/vol) and subjected to peptide desalting with a SepPak C18 column (50 mg, Waters). The column was subsequently washed with 1 ml 100% acetonitrile and 500 µl 80% acetonitrile, 0.5% formic acid. The column was equilibrated with 1 ml 0.1% TFA, the sample was loaded and the column washed again with 1 ml 0.1% TFA. After an additional wash step with 500 µl 0.5% formic acid, peptides were eluted twice with 250 µl 80% acetonitrile, 0.5% formic acid. The organic phase was then removed by vacuum centrifugation and peptides were stored at −80°C. Directly before measurement, peptides were resolved in 20 µl 0.1% formic acid, sonicated for 5 min (water bath), and the sample was then filtered with a prewashed and equilibrated filter (0.45 µm low-protein binding filter, VWR International). Measurements were performed on a liquid chromatography-mass spectrometry system consisting of an Ultimate 3000 nano HPLC directly linked to an Orbitrap XL instrument (Thermo Scientific). Samples were loaded onto a trap column (2 µm, 100 A, 2 cm length) and separated on a 15 cm C18 column (2 µm, 100 A, Thermo Scientific) during a 150 min gradient ranging from 5 to 30% acetonitrile, 0.1% formic acid. Survey spectra were acquired in the orbitrap with a resolution of 60,000 at m/z 400. For protein identification, up to five of the most intense ions of the full scan were sequentially isolated and fragmented by collision induced dissociation. The received data were analysed with the Proteome Discoverer Software version 1.4 (Thermo Scientific) and searched against the H. pylori (strain G27) database (1,501 proteins) in the SEQUEST algorithm. Protein N-terminal acetylation and oxidation of methionins were added as variable modifications, and carbamidomethylation on cysteines as static modifications. Enzyme specificity was set to trypsin, and mass tolerances of the precursor and fragment ions were set to 10 ppm and 0.8 Da, respectively. Only peptides that had X corr values of 1.5, 2.0, 2.25 and 2.5 for charge states +1, +2, +3 and +4, respectively, were considered for data analysis.
Cells, cell-bacteria co-culture and elongation phenotype quantitation assay. Gastric cancer cell lines MKN45 (ref. 45) , KatoIII (ATCC, HTB-103), MKN28 (ref. 46) and AGS (ATCC, CRL-1739) were obtained from ATCC and DSMZ, authenticated by using Short Tandem Repeat (STR) profiling, cultured either sparse or to tight confluence in DMEM (GIBCO, Invitrogen) containing 2 mM L-glutamine (GIBCO, Invitrogen) supplemented with 10% FBS (GIBCO, Invitrogen) and 1% penicillin/streptomycin (GIBCO, Invitrogen). All cell lines were maintained in an incubator at 37°C with 5% CO 2 and 100% humidity, and were routinely mycoplasma-tested twice per year by diamidin-2-phenylindol stain and PCR. Plategrown bacteria were suspended in DMEM and washed by centrifugation at 150g for 5 min in a microcentrifuge. After resuspension in DMEM, OD 600nm was determined and bacteria were added to the overnight serum-deprived cells at different ratios of bacteria/cell (multiplicity of infection, MOI) at 37°C to start the infection. After the indicated time, cells were washed twice with PBS and then lysed with 1% NP-40 in protease and phosphatase inhibitor PBS. HEK293 cells were chosen for CEACAM transfection studies because the cells were found to be negative for human CEACAM expression, and are easily transfectable. HEK cells were grown in six-well plates containing RPMI 1640 medium (Invitrogen) supplemented with 25 mM HEPES buffer and 10% heat-inactivated FBS (Biochrom) for 2 days to approximately 70% confluence. Cells were serum-deprived overnight and infected with H. pylori at an MOI of 50 for the indicated time points in each figure. After infection, the cells were collected in ice-cold PBS containing 1 mM Na 3 VO 4 (Sigma-Aldrich). Elongated AGS cells in each experiment were quantified in five different 0.25 mm 2 fields using an Olympus IX50 phase contrast microscope.
Transfection. CHO cell lines (ATCC) permanently expressing human CEACAM1-4L, mouse CEACAM1-L and rat CEACAM1-L were generated by stably transfecting cells with 4 µg pcDNA3.1-hu CEACAM1-4L, pcDNA3.1-huCEACAM1-4S, pcDNA3.1-msCEACAM1-L, pcDNA3.1-ratCEACAM1-L plasmid (Singer) , respectively, utilizing the Lipofectamine 2000 procedure according to the manufacturer's protocol (Invitrogen). Stable transfected cells were selected in culture medium containing 1 mg ml -1 of Geniticinsulfat (G418, Biochrom). The surface expression of CEACAM1 in individual clones growing in log phase was determined by flow cytometry (FACS calibur, BD). HEK293 cells were transfected with 4 µg of the HA-tagged CEACAM constructs or luciferase reporter constructs (Clontech) for 48 h with TurboFect reagent (Fermentas) according to the manufacturer's instructions.
Western blot. An equal volume of cell lysate was loaded on 8% SDS-PAGE gels and, after electrophoresis, separated proteins were transferred to nitrocellulose membrane (Whatman/GE Healthcare). Membranes were blocked in 5% non-fat milk for 1 h at room temperature and incubated overnight with primary antibodies mAb 18/20 binding to CEACAM1, 3, 5, B3-17 and C5-1X (mono-specific for human CEACAM1, Singer), 4/3/17 (binding to CEACAM1, 5, Genovac) and 5C8C4 (mono-specific for human CEACAM5, Singer), 1H7-4B (mono-specific for human CEACAM6, Singer), 6/40c (mono-specific for human CEACAM8, Singer), Be9.2 (α-rat CEACAM1, kindly provided by W. Reutter, Charite, CBF, Germany), mAb 11-1H (α-rat CEACAM1ΔN, Singer), phosphotyrosine antibody PY-99 (Santa Cruz), α-CagAphosphotyrosine antibody PY-972 (ref. 47) , mouse monoclonal α-CagA antibody (Austral Biologicals), mouse monoclonal α-CEACAM1 (clone D14HD11Genovac/Aldevron) or goat α-GAPDH (Santa Cruz). After washing, membranes were incubated with the secondary antibody (HRP-conjugated α-mouse IgG, Promega) and proteins were detected by ECL western blotting detection reagents. Quantification was performed with LabImage 1D software (INTAS).
Flow cytometry. The Fc-tagged CEACAMs (2.5 µg ml −1 ) were incubated with H. pylori (OD 600 = 1) and subsequently with FITC-conjugated goat α-human IgG (Sigma-Aldrich). After washing with FACS buffer, the samples were analysed by gating on the bacteria (based on forward and sideward scatter) and measuring bacteria-associated fluorescence. In each case, 10,000 events per sample were obtained. Analysis was performed with the FACS CyAn (Beckman Coulter) and the data were evaluated with FlowJo software (Treestar). For analysis of CEACAMmediated HopQ binding, indicated cell types (5 × 10 5 in 50 µl) were incubated with 20 µg ml -1 of H. pylori strain P12 derived, myc and 6× His-tagged recombinant HopQ diluted in 3% FCS/PBS for 1 h on ice. After washing three times with 3% FCS/PBS, samples were labelled with 20 µg ml -1 of mouse α-c-myc mAb (clone 9E10, AbDSerotec) and subsequently with FITC conjugated goat α-mouse F(ab′)2 (Dianova). In parallel, the presence of CEACAMs was controlled by staining cells using the rabbit anti CEA pAb (A0115, Dianova) followed by FITC-conjugated goat α-rabbit F(ab′)2 (Dianova). Background fluorescence was determined using isotype-matched Ig mAb. The stained cell samples were examined in a FACScalibur flow cytometer (BD Biosciences) and the data were analysed utilizing the CellQuest software. Dead cells, identified by propidium iodide staining, were excluded from the measurement.
Immunohistochemistry and immunofluorescence. Following approval from the local ethics committee, paraffin-embedded human normal stomach, gastritis and cancer samples were randomly chosen from the tissue bank of the Institut für Pathologie, Klinikum Bayreuth, Germany. Histological samples were excluded if tissue quality was poor. After antigen retrieval with 10 mM sodium citrate buffer pH 6 in a pressure cooker, the sections were incubated with α-human CEACAM1, 5, 6 and α-rat CEACAM1 antibodies (clone B3-17, 5C8C4, 1H7-4B and Be9.2, respectively). Sections were developed with SignalStain DAB (Cell Signaling) following the manufacturer's instructions. Sections were counterstained with haematoxylin (Morphisto). The automated image acquisition was performed with an Olympus Virtual Slide System VS120.
Visualization of the co-localization of HopQ and CEACAMs co-staining of normal and gastritis sections was performed using HopQ-biotin followed by streptavidin-Cy3 and α-human CEACAM1, 3, 5, 6, 8 clone 6G5j, then by Alexa 488 coupled goat anti-mouse antibody. Cell nuclei were stained with DAPI. DAPI and fluorescent proteins were analysed with the Leica DMI4000B microscope.
Adherence assay. The adherence assay was performed according to Hytönen and co-authors 48 . Briefly, human gastric epithelial cells (MKN45 and AGS) and CEACAM1-transfected CHO cells were grown in antibiotic-free DMEM (Gibco) supplemented with 5% FCS and L-glutamine (2 mM, Sigma-Aldrich) on tissue culture 96-well plates (Bioscience) in 5% CO 2 for 2 days. To visualize H. pylori cells in adhesion assays, OD 600 = 1 bacteria were fluorescence labelled with carboxyfluorescein diacetate-succinimidyl ester (CFDA-SE) (Molecular Probes) and washed with PBS. CFDA-SE was added at a concentration of 10 µM for 30 min at 37°C under constant rotation in the dark. Excess dye was removed by washing three times with PBS. Bacteria were resuspended in PBS until further use. Labelled bacteria were co-incubated (MOI = 10) with the cells at 37°C with gentle agitation for 1 h. After washing with PBS (1 ml, three times) to remove non-adherent bacteria, cells were fixed in paraformaldehyde (2%, 10 min). Bacterial binding was determined by measuring the percentage of cells that bound fluorescent-labelled bacteria using flow cytometry analysis.
IL-8 cytokine ELISA. The AGS cell line was infected with H. pylori as described already, and PBS-incubated control cells served as negative control. The culture supernatants were collected and stored at −20°C until assayed. IL-8 concentration in the supernatant was determined by standard ELISA with commercially available assay kits (Becton Dickinson) according to described procedures.
HopQ-dependency of CagA virulence pathways. If not indicated otherwise, the AGS cell line (ATCC CRL-1730) was infected with the various H. pylori strains for 6 h at an MOI of 50. The cells were then collected in ice-cold PBS in the presence of 1 mM Na 3 VO 4 (Sigma-Aldrich). In each experiment, the number of elongated AGS cells was quantified in ten different 0.25 mm 2 fields using a phase contrast microscope (Olympus IX50). CagA translocation was determined using the indicated antibodies detecting Tyr-phosphorylated CagA. All experiments were performed in triplicate. For inhibition experiments, cells were incubated with the indicated antibodies or peptides before infection.
Confocal microscopy. CHO cells were grown on chamber slides (Thermo Scientific), fixed in paraformaldehyde (4%, 10 min) and blocked with PBS/5% BSA. CFDA-SE labelled bacteria (10 µM for 30 min at 37°C under constant rotation in the dark) at an MOI of 5 were incubated with cells for 1 h at 37°C under constant rotation. After washing five times with PBS, cell membranes were stained with Deep Red (Life Technology) and cell nuclei with DAPI (Life Technology). Confocal images of cells were taken using a Leica SP5 confocal microscope.
Crystallization and structure determination of HopQ AD . HopQ AD was concentrated to 40 mg ml -1 and crystallized by sitting drop vapour diffusion at 20°C using 0.12 M alcohols (0.02 M 1,6-hexanediol; 0.02 M 1-butanol; 0.02 M 1,2-propanediol; 0.02 M 2-propanol; 0.02 M 1,4-butanediol; 0.02 M 1,3-propanediol), 0.1 M Tris (base)/N,N,bis(2-hydroxyethyl)glycine pH 8.5, 20% vol/vol polyethylene glycol (PEG) 500 monomethyl ether (MME); 10% wt/vol PEG 20,000 as a crystallization buffer. Crystals were loop-mounted and flash-cooled in liquid nitrogen. Data were collected at 100 K at beamline Proxima1 (SOLEIL, Gif-sur-Yvette, France) and were indexed, processed and scaled using the XDS package 49 . All crystals were in the P2 1 space group with approximate unit cell dimensions of a = 57.7 Å, b = 57.7 Å, c = 285.7 Å and β = 90.1°and four copies of HopQ 442 per asymmetric unit. Phases were obtained by molecular replacement using the BabA structure (PDB:5F7K) 21 and the program phaser 50, 51 . The models were refined by iterative cycles of manual rebuilding in the graphics program COOT (ref. 52) and maximum likelihood refinement using Refmac5 (ref. 53 ). Supplementary Table 3 summarizes the crystal parameters, data processing and structure refinement statistics.
Amino acid sequence alignment. The amino acid sequence alignment of the N-terminal domains of human, mouse and rat CEACAM1 and human CEACAMs (1, 5, 6 and 8) was performed using CLC main Workbench (CLC bio).
Luciferase reporter assays. CHO-CEACAM1-L cells transfected with various luciferase reporter and control constructs (Clontech) were infected with H. pylori for 5 h and analysed by luciferase assay using the Dual-Luciferase Reporter Assay System according to the manufactures instruction (Promega). Briefly, cells were collected by passive lysis, protein concentration was measured with Precision Red (Cytoskeleton), and the lysates were equalized by adding passive lysis buffer. Luciferase activity was measured using a Plate Luminometer (MITHRAS LB940, Berthold).
Animal experiments. Specific pathogen-free, 120-150 g four-week-old male Sprague-Dawley rats were obtained from Charles River Laboratories. Animals were randomly distributed into the different experimental groups by animal caretakers not involved in the experiments, and criteria for the exclusion of animals were preestablished. Investigator blinding was performed for all assessments of outcome and data, and histology was performed by an independent investigator in a blinded manner. Animals were challenged twice, intragastrically, in groups of eight with ∼1 × 10 8 live H. pylori in two interval days. Group size was determined based on statistical power calculation using data obtained from previous mouse experiments. After 6 weeks of infection, stomachs were removed and sectioned. One part was embedded in paraffin for histological analysis, and another piece was weighted and homogenized to determine c.f.u. per mg stomach. Serial dilutions (1/10, 1/100 and 1/1,000) were plated in WC dent plates. The c.f.u. were counted after 4 days.
The experiments were performed in the specific pathogen-free unit of Zentrum für Präklinische Forschung, Klinikum r. d. Isar der TU München, according to the permission and guidelines of the ethical committee and state veterinary office (Regierung von Oberbayern, 55.2-1.54-2532-160-12).
Statistical analysis. For in vitro experiments, normal distribution was determined by the Shapiro-Wilk test. Normally distributed data were analysed with a two-tailed Student t-test or one-way analysis of variance (ANOVA) with post hoc Bonferroni test (comparing more than two groups) using Graph Pad Prism Software. Data are shown as mean ± s.e.m or s.d. for at least three independent experiments. P values <0.05 were considered significant. For animal studies, power calculations were performed based on previous animal experiments to achieve a two-sided significance of 0.05 while using the lowest possible numbers to comply with the ethical guidelines for experimental animals. Mann-Whitney U-test or ANOVA Kruskal-Wallis and Dunn's multiple comparison tests were used to determine statistical significance.
Data availability. All data generated or analysed during this study are included in this published article (and the Supplementary Information). Coordinates and structure factors for the HopQ AD crystal structure have been deposited in the Protein Data Bank under accession code 5LP2. Accession codes in Supplementary Table 1 refer to UNiprot (http://www.uniprot.org/uniprot/). Bacterial strain and cell lines are available from ATCC (https://www.atcc.org/).
